VTRS
Viatris Inc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$16.50
−0.66%Price chart
Aug 10Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9
ValuationView details →
P/E (Fwd)
6.5x
EV/EBITDA
11.8x
Market Cap
$18.95B
MomentumView details →
1D Return
−0.66%
YTD Return
+32.81%
RSI (14)
47.5
ValuationView details →
P/E (Fwd)
6.5x
EV/EBITDA
11.8x
Market Cap
$18.95B
RSI (14)
47.5
MomentumView details →
1D Return
−0.66%
YTD Return
+32.81%
SummaryUpdated Jun 1, 2026
Viatris Inc. (NASDAQ:VTRS) is a global healthcare company formed in 2020 through the merger of Mylan N.V. and Pfizer's Upjohn division. The company traces its roots back to 1961 and represents one of the world's largest generic and specialty pharmaceutical companies. Headquartered in Canonsburg, Pennsylvania, Viatris operates across more than 165 countries and serves over one billion patients annually with a diverse portfolio of prescription medicines, biosimilars, and active pharmaceutical ingredients.
Similar companies
Latest newsMore news →
The Supreme Court of India upheld the Telangana High Court's decision not to initiate contempt proceedings against IQuest Enterprises Pvt. Ltd., ruling that a clarificatory statement made before a court does not constitute a binding undertaking for contempt purposes.9d agoShield Therapeutics announced it will assume full commercial control of ACCRUFeR in the US from Viatris starting 30 September, without an upfront cash payment, in exchange for a reduced royalty on US net sales over five years.13d ago